GlassScriptPhysician profile
Damon Fellman
NPI 1982671830
$9,277.97
in general payments reported to CMS, 2019-2025
26 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $4,719 · 2021: $289 · 2022: $619 · 2023: $1,205 · 2024: $593 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,588 · Consulting Fee: $300 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,588.32 |
| Consulting Fee | $300.00 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,711.75 | 2019-2020 | |
| Abbvie INC. | $681.63 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $574.55 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Lundbeck LLC | $426.70 | 2022-2025 | Vyepti, Rexulti |
| Biogen, INC. | $381.99 | 2021-2025 | Tysabri, Vumerity |
| Lilly USA, LLC | $346.30 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Novartis Pharmaceuticals Corporation | $255.38 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $240.13 | 2023-2025 | Rexulti |
| Alexion Pharmaceuticals, INC. | $193.11 | 2019-2025 | Ultomiris |
| Amgen INC. | $149.59 | 2021-2024 | Aimovig |
| Pfizer INC. | $146.04 | 2021-2025 | |
| Ucb, INC. | $144.00 | 2023-2024 | Briviact, Rystiggo |
| Janssen Pharmaceuticals, INC | $142.52 | 2021-2022 | |
| Genentech USA, INC. | $138.74 | 2020-2024 | Ocrevus, Enspryng |
| Glaxosmithkline, LLC. | $125.06 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $118.44 | 2022-2024 | Mavenclad |
| Argenx US, INC. | $82.58 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Celgene Corporation | $81.46 | 2021-2025 | Zeposia |
| Tg Therapeutics, INC. | $72.16 | 2023 | |
| Sk Life Science, INC. | $71.00 | 2022-2025 | |
| Acorda Therapeutics, INC | $60.19 | 2019 | |
| Csl Behring | $59.86 | 2021-2023 | Hizentra |
| Impel Pharmaceuticals INC. | $23.08 | 2022 | |
| Grifols USA, LLC | $19.16 | 2023 | Gamunex-C |
| Neurocrine Biosciences, INC. | $17.55 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Fellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.